IL94081A - Receptors for mass-interferon-gamma, their production and pharmaceutical preparations containing them - Google Patents

Receptors for mass-interferon-gamma, their production and pharmaceutical preparations containing them

Info

Publication number: IL94081A
Authority: IL; Israel
Prior art keywords: receptor; plasmid; ifn; fragment; protein
Prior art date: 1989-04-19

Application number

IL9408190A

Other languages

English (en)

Hebrew (he)

Other versions

IL94081A0 (en

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-04-19

Filing date

1990-04-13

Publication date

1996-09-12

1990-04-13 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

1991-01-31 Publication of IL94081A0 publication Critical patent/IL94081A0/xx

1996-09-12 Publication of IL94081A publication Critical patent/IL94081A/en

Links

238000004519 manufacturing process Methods 0.000 title claims description 48
239000008194 pharmaceutical composition Substances 0.000 title claims description 8
108010085650 interferon gamma receptor Proteins 0.000 title description 4
238000000034 method Methods 0.000 claims abstract description 30
108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 19
108020003175 receptors Proteins 0.000 claims description 324
102000005962 receptors Human genes 0.000 claims description 322
108090000623 proteins and genes Proteins 0.000 claims description 221
102000004169 proteins and genes Human genes 0.000 claims description 181
108010074328 Interferon-gamma Proteins 0.000 claims description 154
102100037850 Interferon gamma Human genes 0.000 claims description 153
230000027455 binding Effects 0.000 claims description 48
230000014509 gene expression Effects 0.000 claims description 39
238000002360 preparation method Methods 0.000 claims description 34
239000013598 vector Substances 0.000 claims description 22
239000013604 expression vector Substances 0.000 claims description 18
238000011282 treatment Methods 0.000 claims description 10
241000701447 unidentified baculovirus Species 0.000 claims description 9
241000238631 Hexapoda Species 0.000 claims description 6
230000001086 cytosolic effect Effects 0.000 claims description 6
238000012546 transfer Methods 0.000 claims description 6
208000023275 Autoimmune disease Diseases 0.000 claims description 5
208000006313 Delayed Hypersensitivity Diseases 0.000 claims description 5
239000013543 active substance Substances 0.000 claims description 5
208000037976 chronic inflammation Diseases 0.000 claims description 5
230000006020 chronic inflammation Effects 0.000 claims description 5
239000003937 drug carrier Substances 0.000 claims description 4
239000000463 material Substances 0.000 claims description 4
201000006417 multiple sclerosis Diseases 0.000 claims description 4
239000000556 agonist Substances 0.000 claims description 3
239000005557 antagonist Substances 0.000 claims description 3
238000012258 culturing Methods 0.000 claims description 3
230000008569 process Effects 0.000 claims description 2
125000003275 alpha amino acid group Chemical group 0.000 claims 1
239000013612 plasmid Substances 0.000 description 380
150000001413 amino acids Chemical class 0.000 description 229
239000012634 fragment Substances 0.000 description 217
235000018102 proteins Nutrition 0.000 description 179
101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 168
210000004027 cell Anatomy 0.000 description 149
235000001014 amino acid Nutrition 0.000 description 125
108091008146 restriction endonucleases Proteins 0.000 description 121
108020004414 DNA Proteins 0.000 description 101
238000003776 cleavage reaction Methods 0.000 description 74
239000002773 nucleotide Substances 0.000 description 74
125000003729 nucleotide group Chemical group 0.000 description 74
230000007017 scission Effects 0.000 description 74
241000588724 Escherichia coli Species 0.000 description 51
108010076504 Protein Sorting Signals Proteins 0.000 description 50
238000010276 construction Methods 0.000 description 50
239000002609 medium Substances 0.000 description 28
239000000872 buffer Substances 0.000 description 27
101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 24
239000000203 mixture Substances 0.000 description 23
239000000243 solution Substances 0.000 description 22
230000008488 polyadenylation Effects 0.000 description 19
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 18
210000003705 ribosome Anatomy 0.000 description 18
108020004705 Codon Proteins 0.000 description 17
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
239000002953 phosphate buffered saline Substances 0.000 description 15
108091003079 Bovine Serum Albumin Proteins 0.000 description 14
239000012091 fetal bovine serum Substances 0.000 description 14
239000006228 supernatant Substances 0.000 description 14
108090000204 Dipeptidase 1 Proteins 0.000 description 13
102000006635 beta-lactamase Human genes 0.000 description 13
230000010076 replication Effects 0.000 description 13
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 12
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 12
108700026244 Open Reading Frames Proteins 0.000 description 9
239000004202 carbamide Substances 0.000 description 9
230000000694 effects Effects 0.000 description 9
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 9
229910002092 carbon dioxide Inorganic materials 0.000 description 8
229910000162 sodium phosphate Inorganic materials 0.000 description 8
238000001890 transfection Methods 0.000 description 8
108091026890 Coding region Proteins 0.000 description 7
108010022394 Threonine synthase Proteins 0.000 description 7
238000001042 affinity chromatography Methods 0.000 description 7
102000004419 dihydrofolate reductase Human genes 0.000 description 7
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 7
239000003446 ligand Substances 0.000 description 7
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 7
239000000725 suspension Substances 0.000 description 7
102000004190 Enzymes Human genes 0.000 description 6
108090000790 Enzymes Proteins 0.000 description 6
241001596967 Escherichia coli M15 Species 0.000 description 6
108010054278 Lac Repressors Proteins 0.000 description 6
239000001569 carbon dioxide Substances 0.000 description 6
239000013522 chelant Substances 0.000 description 6
238000004587 chromatography analysis Methods 0.000 description 6
238000010790 dilution Methods 0.000 description 6
239000012895 dilution Substances 0.000 description 6
229940088598 enzyme Drugs 0.000 description 6
239000000499 gel Substances 0.000 description 6
238000000746 purification Methods 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
239000001488 sodium phosphate Substances 0.000 description 6
229960003339 sodium phosphate Drugs 0.000 description 6
235000011008 sodium phosphates Nutrition 0.000 description 6
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 6
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
108010050904 Interferons Proteins 0.000 description 5
102000014150 Interferons Human genes 0.000 description 5
239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 5
125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 5
239000007983 Tris buffer Substances 0.000 description 5
241000700605 Viruses Species 0.000 description 5
239000002671 adjuvant Substances 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
238000011534 incubation Methods 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
239000012528 membrane Substances 0.000 description 5
238000002703 mutagenesis Methods 0.000 description 5
231100000350 mutagenesis Toxicity 0.000 description 5
108010066381 preproinsulin Proteins 0.000 description 5
239000011347 resin Substances 0.000 description 5
229920005989 resin Polymers 0.000 description 5
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
241000272186 Falco columbarius Species 0.000 description 4
229960000723 ampicillin Drugs 0.000 description 4
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
230000000840 anti-viral effect Effects 0.000 description 4
LZCZIHQBSCVGRD-UHFFFAOYSA-N benzenecarboximidamide;hydron;chloride Chemical compound [Cl-].NC(=[NH2+])C1=CC=CC=C1 LZCZIHQBSCVGRD-UHFFFAOYSA-N 0.000 description 4
239000013553 cell monolayer Substances 0.000 description 4
238000005119 centrifugation Methods 0.000 description 4
238000001514 detection method Methods 0.000 description 4
238000000502 dialysis Methods 0.000 description 4
238000000605 extraction Methods 0.000 description 4
238000002955 isolation Methods 0.000 description 4
239000007788 liquid Substances 0.000 description 4
229920002401 polyacrylamide Polymers 0.000 description 4
239000000843 powder Substances 0.000 description 4
230000000063 preceeding effect Effects 0.000 description 4
239000007787 solid Substances 0.000 description 4
238000006467 substitution reaction Methods 0.000 description 4
238000012360 testing method Methods 0.000 description 4
238000002255 vaccination Methods 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
108010039627 Aprotinin Proteins 0.000 description 3
108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 3
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
108010025815 Kanamycin Kinase Proteins 0.000 description 3
125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
239000000020 Nitrocellulose Substances 0.000 description 3
241000714474 Rous sarcoma virus Species 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000003321 amplification Effects 0.000 description 3
229960004405 aprotinin Drugs 0.000 description 3
230000000120 cytopathologic effect Effects 0.000 description 3
239000003599 detergent Substances 0.000 description 3
239000003995 emulsifying agent Substances 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 3
229940047124 interferons Drugs 0.000 description 3
229930027917 kanamycin Natural products 0.000 description 3
229960000318 kanamycin Drugs 0.000 description 3
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 3
229930182823 kanamycin A Natural products 0.000 description 3
239000003550 marker Substances 0.000 description 3
238000010369 molecular cloning Methods 0.000 description 3
229920001220 nitrocellulos Polymers 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
238000003199 nucleic acid amplification method Methods 0.000 description 3
239000000825 pharmaceutical preparation Substances 0.000 description 3
239000003755 preservative agent Substances 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
238000003127 radioimmunoassay Methods 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
102220073915 rs144744634 Human genes 0.000 description 3
102220099379 rs770702450 Human genes 0.000 description 3
239000012723 sample buffer Substances 0.000 description 3
238000004513 sizing Methods 0.000 description 3
239000003381 stabilizer Substances 0.000 description 3
238000010561 standard procedure Methods 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 2
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
108010001857 Cell Surface Receptors Proteins 0.000 description 2
108020004635 Complementary DNA Proteins 0.000 description 2
101150074155 DHFR gene Proteins 0.000 description 2
102000053602 DNA Human genes 0.000 description 2
229920002307 Dextran Polymers 0.000 description 2
241000272184 Falconiformes Species 0.000 description 2
102000000588 Interleukin-2 Human genes 0.000 description 2
108010002350 Interleukin-2 Proteins 0.000 description 2
102000010789 Interleukin-2 Receptors Human genes 0.000 description 2
108010038453 Interleukin-2 Receptors Proteins 0.000 description 2
125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 description 2
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 2
108091026898 Leader sequence (mRNA) Proteins 0.000 description 2
108010074338 Lymphokines Proteins 0.000 description 2
102000008072 Lymphokines Human genes 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
230000004988 N-glycosylation Effects 0.000 description 2
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
101710182846 Polyhedrin Proteins 0.000 description 2
239000004793 Polystyrene Substances 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
229920002125 Sokalan® Polymers 0.000 description 2
108091081024 Start codon Proteins 0.000 description 2
241000473945 Theria <moth genus> Species 0.000 description 2
108091036066 Three prime untranslated region Proteins 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
239000000654 additive Substances 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
150000001450 anions Chemical class 0.000 description 2
239000000427 antigen Substances 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
239000012888 bovine serum Substances 0.000 description 2
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
239000012876 carrier material Substances 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
229960003677 chloroquine Drugs 0.000 description 2
WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 2
210000000349 chromosome Anatomy 0.000 description 2
238000010367 cloning Methods 0.000 description 2
238000013329 compounding Methods 0.000 description 2
239000005289 controlled pore glass Substances 0.000 description 2
239000013078 crystal Substances 0.000 description 2
229960002086 dextran Drugs 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
229960000789 guanidine hydrochloride Drugs 0.000 description 2
235000014304 histidine Nutrition 0.000 description 2
230000006698 induction Effects 0.000 description 2
229940079322 interferon Drugs 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
102000006240 membrane receptors Human genes 0.000 description 2
108020004999 messenger RNA Proteins 0.000 description 2
229960000485 methotrexate Drugs 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
229920002223 polystyrene Polymers 0.000 description 2
125000002924 primary amino group Chemical class [H]N([H])* 0.000 description 2
239000000047 product Substances 0.000 description 2
-1 pyran Chemical class 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
239000011550 stock solution Substances 0.000 description 2
229930101283 tetracycline Natural products 0.000 description 2
230000010474 transient expression Effects 0.000 description 2
238000013519 translation Methods 0.000 description 2
230000014621 translational initiation Effects 0.000 description 2
POSZUTFLHGNLHX-KSBRXOFISA-N tris maleate Chemical compound OCC(N)(CO)CO.OCC(N)(CO)CO.OC(=O)\C=C/C(O)=O POSZUTFLHGNLHX-KSBRXOFISA-N 0.000 description 2
238000005406 washing Methods 0.000 description 2
ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 1
FJLUATLTXUNBOT-UHFFFAOYSA-N 1-Hexadecylamine Chemical compound CCCCCCCCCCCCCCCCN FJLUATLTXUNBOT-UHFFFAOYSA-N 0.000 description 1
PYAFUXYGTYWWBP-UHFFFAOYSA-N 19-methoxynonadecane-1,2,3-triol Chemical compound COCCCCCCCCCCCCCCCCC(O)C(O)CO PYAFUXYGTYWWBP-UHFFFAOYSA-N 0.000 description 1
XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
241000271566 Aves Species 0.000 description 1
235000014469 Bacillus subtilis Nutrition 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
108010077805 Bacterial Proteins Proteins 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
241000282552 Chlorocebus aethiops Species 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
102000036364 Cullin Ring E3 Ligases Human genes 0.000 description 1
230000004543 DNA replication Effects 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
102000004533 Endonucleases Human genes 0.000 description 1
YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
241000701959 Escherichia virus Lambda Species 0.000 description 1
241000701988 Escherichia virus T5 Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
241000192125 Firmicutes Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
239000012981 Hank's balanced salt solution Substances 0.000 description 1
102100026720 Interferon beta Human genes 0.000 description 1
108090000467 Interferon-beta Proteins 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 description 1
101710184243 Intestinal-type alkaline phosphatase Proteins 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 description 1
125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 description 1
125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
102000016943 Muramidase Human genes 0.000 description 1
108010014251 Muramidase Proteins 0.000 description 1
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
241001045988 Neogene Species 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
230000004989 O-glycosylation Effects 0.000 description 1
REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000015731 Peptide Hormones Human genes 0.000 description 1
108010038988 Peptide Hormones Proteins 0.000 description 1
102100029251 Phagocytosis-stimulating peptide Human genes 0.000 description 1
241000286209 Phasianidae Species 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
239000004365 Protease Substances 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
108010034634 Repressor Proteins Proteins 0.000 description 1
102000009661 Repressor Proteins Human genes 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
208000006666 Shwartzman Phenomenon Diseases 0.000 description 1
231100000702 Shwartzman phenomenon Toxicity 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
101710120037 Toxin CcdB Proteins 0.000 description 1
206010044565 Tremor Diseases 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
108010084754 Tuftsin Proteins 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
LUXUAZKGQZPOBZ-SAXJAHGMSA-N [(3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (Z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O LUXUAZKGQZPOBZ-SAXJAHGMSA-N 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
230000009471 action Effects 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
230000004075 alteration Effects 0.000 description 1
229940037003 alum Drugs 0.000 description 1
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
239000001166 ammonium sulphate Substances 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
238000003556 assay Methods 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
244000309466 calf Species 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
229940041514 candida albicans extract Drugs 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
238000012761 co-transfection Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
239000012050 conventional carrier Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
230000007423 decrease Effects 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
238000013461 design Methods 0.000 description 1
229960000633 dextran sulfate Drugs 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
229960005542 ethidium bromide Drugs 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000007789 gas Substances 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000005484 gravity Effects 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000003308 immunostimulating effect Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
239000000411 inducer Substances 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000012194 insect media Substances 0.000 description 1
229960003130 interferon gamma Drugs 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
238000001155 isoelectric focusing Methods 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000002502 liposome Substances 0.000 description 1
244000144972 livestock Species 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
239000004325 lysozyme Substances 0.000 description 1
229960000274 lysozyme Drugs 0.000 description 1
235000010335 lysozyme Nutrition 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
239000000178 monomer Substances 0.000 description 1
229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
230000035772 mutation Effects 0.000 description 1
101150091879 neo gene Proteins 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
229910052759 nickel Inorganic materials 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000002674 ointment Substances 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
239000006201 parenteral dosage form Substances 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000000813 peptide hormone Substances 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
239000006187 pill Substances 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
239000004584 polyacrylic acid Substances 0.000 description 1
229920001515 polyalkylene glycol Polymers 0.000 description 1
229920000447 polyanionic polymer Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000009465 prokaryotic expression Effects 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
238000004366 reverse phase liquid chromatography Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000012216 screening Methods 0.000 description 1
230000028327 secretion Effects 0.000 description 1
229940083575 sodium dodecyl sulfate Drugs 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
238000003836 solid-state method Methods 0.000 description 1
241000894007 species Species 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
239000012137 tryptone Substances 0.000 description 1
229940035670 tuftsin Drugs 0.000 description 1
IESDGNYHXIOKRW-LEOABGAYSA-N tuftsin Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](CCCNC(N)=N)C(O)=O IESDGNYHXIOKRW-LEOABGAYSA-N 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
230000007442 viral DNA synthesis Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
239000012138 yeast extract Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Cell Biology (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

IL9408190A 1989-04-19 1990-04-13 Receptors for mass-interferon-gamma, their production and pharmaceutical preparations containing them IL94081A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP89810295		1989-04-19

Publications (2)

Publication Number	Publication Date
IL94081A0 IL94081A0 (en)	1991-01-31
IL94081A true IL94081A (en)	1996-09-12

Family

ID=8203144

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL9408190A IL94081A (en)	1989-04-19	1990-04-13	Receptors for mass-interferon-gamma, their production and pharmaceutical preparations containing them

Country Status (11)

Country	Link
EP (1)	EP0393502B1 (de)
JP (1)	JPH02303490A (de)
AT (1)	ATE132191T1 (de)
AU (1)	AU625866B2 (de)
CA (1)	CA2014752A1 (de)
DE (1)	DE69024398T2 (de)
DK (1)	DK0393502T3 (de)
IE (1)	IE901373L (de)
IL (1)	IL94081A (de)
NZ (1)	NZ233308A (de)
ZA (1)	ZA902843B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL88378A (en) *	1988-11-14	2000-11-21	Yeda Res & Dev	Human interferon-gamma binding proteins their manufacture and pharmaceutical compositions comprising them
IL91562A0 (en) *	1989-09-07	1990-04-29	Yeda Res & Dev	Interferon-gamma receptor fragment and its production
JPH05502037A (ja) *	1990-04-24	1993-04-15	シェリング・コーポレーション	可溶性のトランケートされたガンマ―インターフェロン受容体
WO1994012531A1 (en) *	1992-11-20	1994-06-09	Schering Corporation	Antagonists of human gamma interferon
DE69322289T2 (de)	1992-12-29	1999-05-20	Genentech, Inc., South San Francisco, Calif.	Behandlung von entzündlichen darmerkrankungen mit interferon-gamma-inhibitoren
CA2114168A1 (en) *	1993-03-05	1994-09-06	Zlatko Dembic	Chimeric human interferon-gamma-receptor/immunoglobulin polypeptides
IL107378A (en) *	1993-10-24	2005-05-17	Yeda Res & Dev	SOLUBLE INTERFERON alpha-RECEPTOR, ITS PREPARATION AND USE
GB2304342A (en) *	1995-08-18	1997-03-19	Univ Manchester	Pharmaceutical comprising either an inhibitor or a stimulator of interferon gamma
US20020025316A1 (en)	1995-08-18	2002-02-28	Ferguson Mark Williams James	Pharmaceutical composition containing inhibitors of interferon-gamma
US6045997A (en) *	1995-11-23	2000-04-04	Duke University	Materials and methods relating to the identification and sequencing of the BRCA2 cancer susceptibility gene and uses thereof
US7020843B2 (en)	1999-11-30	2006-03-28	Uhc Llc	Method and system for implementing a browser object container
US6606103B1 (en)	1999-11-30	2003-08-12	Uhc Llc	Infinite resolution scheme for graphical user interface object
CU23229A1 (es) *	2002-05-10	2007-09-26	Ct Ingenieria Genetica Biotech	ANTAGONISTA QUIMéRICO ANTH1
US7608430B2 (en)	2005-07-08	2009-10-27	Regeneron Pharmaceuticals, Inc.	Interferon-γ antagonists and therapeutic uses thereof
GB0624071D0 (en) *	2006-12-01	2007-01-10	Bioline Res Ltd	Purification methods and materials
WO2025049345A1 (en)	2023-08-25	2025-03-06	Proteologix Us Inc.	Anti-il-13 multispecific antibody constructs and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL78444A (en) *	1986-04-08	1992-05-25	Yeda Res & Dev	Human gamma interferon-specific receptor protein,antibody against said protein,and compositions containing said protein and antibody

1990
- 1990-04-11 DK DK90106992.2T patent/DK0393502T3/da active
- 1990-04-11 AU AU53093/90A patent/AU625866B2/en not_active Ceased
- 1990-04-11 EP EP90106992A patent/EP0393502B1/de not_active Expired - Lifetime
- 1990-04-11 AT AT90106992T patent/ATE132191T1/de not_active IP Right Cessation
- 1990-04-11 DE DE69024398T patent/DE69024398T2/de not_active Expired - Fee Related
- 1990-04-12 NZ NZ233308A patent/NZ233308A/en unknown
- 1990-04-12 ZA ZA902843A patent/ZA902843B/xx unknown
- 1990-04-13 IL IL9408190A patent/IL94081A/en not_active IP Right Cessation
- 1990-04-18 IE IE901373A patent/IE901373L/xx unknown
- 1990-04-18 CA CA002014752A patent/CA2014752A1/en not_active Abandoned
- 1990-04-19 JP JP2104370A patent/JPH02303490A/ja active Pending

Also Published As

Publication number	Publication date
EP0393502A1 (de)	1990-10-24
CA2014752A1 (en)	1990-10-19
DE69024398T2 (de)	1996-06-13
AU5309390A (en)	1990-11-08
ATE132191T1 (de)	1996-01-15
IE901373L (en)	1990-10-19
IL94081A0 (en)	1991-01-31
DK0393502T3 (da)	1996-03-04
EP0393502B1 (de)	1995-12-27
AU625866B2 (en)	1992-07-16
NZ233308A (en)	1992-11-25
JPH02303490A (ja)	1990-12-17
DE69024398D1 (de)	1996-02-08
ZA902843B (en)	1990-12-28

Legal Events

Date	Code	Title
1997-02-18	FF	Patent granted
1997-04-15	KB	Patent renewed
2001-06-14	RH	Patent void

Publication	Publication Date	Title
EP0393502B1 (de)	1995-12-27	Auflösbare Interferon-gamma-Rezeptoren sowie Verfahren zu deren Herstellung
US5712121A (en)	1998-01-27	Chimeric interleukin 5-receptor/immunoglobulin polypeptides
AU603775B2 (en)	1990-11-29	Nucleic acid encoding the alpha or beta chains of inhibin and method for synthesizing polypeptides using such nucleic acid
FI93025C (fi)	1995-02-10	Rekombinantti lymfotoksiini
Brothers et al.	1988	Characterization of a surface antigen of Eimeria tenella sporozoites and synthesis from a cloned cDNA in Escherichia coli
WO1993011162A1 (en)	1993-06-10	Bispecific antibody heterodimers
IL105271A (en)	1995-07-31	Tumor nectosis factor and variants
CA2264200A1 (en)	1998-02-26	Human endokine alpha
CA2084514A1 (en)	1992-01-11	O-glycosylated ifn-alpha
WO1996031526A1 (en)	1996-10-10	Anti-obesity agents
EP0439535B1 (de)	1996-11-20	Für die gamma-untereinheit des rezeptors mit hoher affinität für immunglobulin e kodierende cdnas
CA2087494C (en)	2008-10-07	Soluble ldl receptor, its production and use
US5496926A (en)	1996-03-05	Process of preparing a soluble LDL receptor
Van Mellaert et al.	1994	Efficient secretion of biologically active mouse tumor necrosis factor α by Streptomyces lividans
CA2058003A1 (en)	1992-06-28	Human-interleukin-5 receptor
AU593118B2 (en)	1990-02-01	Polypeptide competitor for immunoglobulin e
Jacobson et al.	1989	Expression and secretion of biologically active echistatin in Saccharomyces cerevisiae
EP0676413B9 (de)	2005-05-18	Interferon alpha/beta bindendes Protein, seine Herstellung und Anwendung
KR100688051B1 (ko)	2007-02-28	각질세포-유래된 인터페론
AU702379B2 (en)	1999-02-18	Novel feline cytokine protein
EP0614981A1 (de)	1994-09-14	Menschliche Chimäre Gamma-Interferon Rezeptor/Immunoglobulin Polypeptide
AU692450B2 (en)	1998-06-11	Method for recombinant production of biologically active polypeptides
US20060003407A1 (en)	2006-01-05	Methods for preparing highly active april ligand polypeptides
Murata et al.	1993	Production of poly (L-aspartyl-L-phenylalanine) in Escherichia coli
US20040053249A1 (en)	2004-03-18	Fas ligand-fused proteins